Allergan to launch wrinkle filler Juvederm through experience trial

By E. Janene Geiss

Philadelphia, Sept. 26 - Allergan, Inc. said Tuesday that it is launching its "next-generation" hyaluronic acid dermal filler products, Juvederm Ultra and Juvederm Ultra Plus, through an experience trial involving a group of physicians with expertise in facial aesthetics, in advance of nationwide product availability in January.

The Irvine, Calif., pharmaceutical company said in a news release that it will begin accepting physician pre-orders for the products Nov. 1 via its nationwide sales force.

The experience trial is a multi-center, open-label trial designed to gain relevant information on physicians' use of Juvederm and to evaluate the persistence of and patient satisfaction with the products in daily clinical practice.

The Food and Drug Administration approved the Juvederm dermal filler family of products in June. Like the company's other wrinkle filler product, Botox, Juvederm is a cross-linked formulation for more versatility in contouring and volumizing of facial wrinkles and folds.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.